GenesisTissue
Develops personalized 3D bioprinted regenerative tissue implants for breast reconstruction and cosmetic surgery, replacing silicone implants with bioresorbable scaffolds that promote natural tissue regeneration.
- CEO / Founder
- Katie Weimer
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $2.5M
- Latest Round
- Strategic Investment
- Key Investors
- Tiger Aesthetics Medical, Innosphere Ventures
Technology & Products
Key Products
Regenerative Breast Tissue platform (investigational 3D bioprinted scaffolds)
Technological Advantage
Proprietary 3D bioprinting platform designed to replicate native tissue architecture; leverages CEO's expertise from 3D Systems' regenerative medicine division; strategic partnership with Tiger Aesthetics for clinical and commercial development.
Differentiation
Value Proposition
Offers a regenerative alternative to silicone implants by providing patient-specific 3D bioprinted scaffolds that degrade and are replaced by the patient's own tissue, aiming for natural, lifelong outcomes and reduced rejection risks.
How They Differentiate
Focuses exclusively on personalized regenerative tissue implants using 3D bioprinting, unlike traditional implant manufacturers or generic bioprinting companies; aims to move beyond repair to true regeneration with patient-specific solutions.
Market & Competition
Target Customers
Healthcare providers, hospitals, plastic surgeons, breast reconstruction patients
Industry Verticals
Medical; Healthcare; Cosmetic Surgery
Competitors
Prellis Biologics; 3D Systems (Healthcare Solutions); CELLINK (BICO)
Growth & Milestones
Growth Metrics
Strategic investment received from Tiger Aesthetics Medical, LLC on November 3, 2025; founded in 2024; based at CSU Spur campus in Denver, Colorado as of March 4, 2026; no revenue, sales, employee count, or funding amount figures disclosed.
Major Milestones
Founded in 2024; Strategic investment from Tiger Aesthetics in late 2025; Launch of Regenerative Breast Tissue platform (investigational stage)